1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Strides Hits Pause On Stelis Injectables Investments

Makes A Strong Showing In Q1

 
• By Vibha Ravi

Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.

Pause
Strides Suspended Additional Investments In Stelis's Injectables • Source: Shutterstock

India's Strides Pharma Science Limited has decided to pause further investments in the long-gestating sterile injectables business under Stelis BioPharma while retaining its commitment to invest up to $40m in Stelis itself.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business